Jump to main content
Jump to site search

Issue 3, 2011
Previous Article Next Article

A pretargeted nanoparticle system for tumor cell labeling

Author affiliations


Nanoparticle-based cancer diagnostics and therapeutics can be significantly enhanced by selective tissue localization, but the strategy can be complicated by the requirement of a targeting ligand conjugated on nanoparticles, that is specific to only one or a limited few types of neoplastic cells, necessitating the development of multiple nanoparticle systems for different diseases. Here, we present a new nanoparticle system that capitalizes on a targeting pretreatment strategy, where a circulating fusion protein (FP) selectively prelabels the targeted cellular epitope, and a biotinylated iron oxide nanoparticle serves as a secondary label that binds to the FP on the target cell. This approach enables a single nanoparticle formulation to be used with any one of existing fusion proteins to bind a variety of target cells. We demonstrated this approach with two fusion proteins against two model cancer cell lines: lymphoma (Ramos) and leukemia (Jurkat), which showed 72.2% and 91.1% positive labeling, respectively. Notably, TEM analysis showed that a large nanoparticle population was endocytosed via attachment to the non-internalizing CD20 epitope.

Graphical abstract: A pretargeted nanoparticle system for tumor cell labeling

Back to tab navigation

Supplementary files

Article information

19 Apr 2010
13 Oct 2010
First published
24 Nov 2010

Mol. BioSyst., 2011,7, 742-748
Article type

A pretargeted nanoparticle system for tumor cell labeling

J. Gunn, S. I. Park, O. Veiseh, O. W. Press and M. Zhang, Mol. BioSyst., 2011, 7, 742
DOI: 10.1039/C005154C

Search articles by author